Maria Reyes Bernabe Caro

Profesora Asociada CIS
mbernabe@us.es
Área de conocimiento: Medicina
Departamento: Medicina
Grupo: ONCOLOGÍA MOLECULAR Y NUEVAS TERAPIAS (CTS-629)
Tipo Año Título Fuente
Artículo2023 Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain Cost Effectiveness and Resource Allocation
Artículo2022 A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial ANNALS OF ONCOLOGY
Artículo2022 Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis Oncology and Therapy
Artículo2022 Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program ONCOTARGET
Artículo2022 Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
Artículo2022 Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics BMC CANCER
Artículo2022 Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. JOURNAL OF THORACIC ONCOLOGY
Artículo2022 First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial JOURNAL OF THORACIC ONCOLOGY
Revisión2022 Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis ESMO open
Artículo2022 Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial) JOURNAL OF CLINICAL ONCOLOGY
Artículo2022 PECATI: a multicentric, open-label, single-arm phase II study to evaluate the efficacy and safety of pembrolizumab and lenvatinib in pretreated B3-thymoma and thymic carcinoma patients Clinical Lung Cancer
Artículo2022 Real-world analysis of nivolumab and atezolizumab efficacy in previously treated patients with advanced non-small cell lung cancer PHARMACEUTICALS
Artículo2022 RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer CANCER
Artículo2022 SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021) CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2022 Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy JOURNAL FOR IMMUNOTHERAPY OF CANCER
Artículo2021 Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial Clinical and translational medicine
Artículo2021 Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial JOURNAL FOR IMMUNOTHERAPY OF CANCER
Artículo2021 Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial Molecular Oncology
Artículo2021 Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab Translational Lung Cancer Research
Artículo2021 Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial ESMO open
Revisión2021 Pd-(L)1 inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer patients with high pd-l1 expression: a network meta-analysis JOURNAL OF CLINICAL MEDICINE
Artículo2021 Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy CLINICAL CANCER RESEARCH
Artículo2021 Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data BMC CANCER
Artículo2021 Veliparib in combination with platinum-based chemotherapy for first-line treatment of advanced squamous cell lung cancer: a randomized, multicenter phase III study JOURNAL OF CLINICAL ONCOLOGY
Artículo2020 Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study JAMA Oncology
Artículo2020 Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL) Lung Cancer
Artículo2020 Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial LANCET ONCOLOGY
Revisión2020 Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy CANCERS
Artículo2020 Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation Cancer Epidemiology
Artículo2020 The roles of imprinted SLC22A18 and SLC22A18AS gene overexpression caused by promoter CPG island hypomethylation as diagnostic and prognostic biomarkers for non-small cell lung cancer patients CANCERS
Artículo2019 Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2019 Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance Lung Cancer
Artículo2019 Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping ANNALS OF ONCOLOGY
Artículo2019 Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study) Translational Lung Cancer Research
Artículo2019 Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer NEW ENGLAND JOURNAL OF MEDICINE
Artículo2019 Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer EUROPEAN JOURNAL OF CANCER CARE
Revisión2017 What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer? EUROPEAN JOURNAL OF CANCER
Artículo2016 Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07 Anticancer Research: international journal of cancer research and treatment
Artículo2016 Selumetinib in the treatment of non-small-cell lung cancer FUTURE ONCOLOGY
Artículo2015 SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015 CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2014 Determination of Neuronal Antibodies in Suspected and Definite Creutzfeldt-Jakob Disease JAMA NEUROLOGY
Artículo2013 Postnatal fate of the ultimobranchial remnants in the rat thyroid gland JOURNAL OF MORPHOLOGY
Artículo2012 Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial LANCET ONCOLOGY
Artículo2008 A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer CLINICAL & TRANSLATIONAL ONCOLOGY
Artículo2008 Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+metastatic breast cancer CANCER CHEMOTHERAPY AND PHARMACOLOGY
Letter2005 Bone Hodgkin lymphoma: Two patients and literature review [1] REVISTA CLINICA ESPANOLA
Artículo2005 Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma
Revisión2004 Tratamiento quimioterápico adyuvante y neoadyuvante del cáncer de mama Ciencia Ginecologika
Artículo2002 Comparative immunohistochemical study of normal, hyperplastic and neoplastic C cells of the rat thyroid gland CELL AND TISSUE RESEARCH
Editorial2002 Valores de los marcadores séricos tumorales en el diagnóstico precoz de las neoplasias y en los exámenes de salud a personas asintomáticas REVISTA CLINICA ESPANOLA
Artículo2001 Degeneración cerebelosa paraneoplásica y carcinoma de ovario Oncología
Letter2001 Hepatoblastoma in an adult MEDICINA CLINICA
Letter1999 "Old" terms for "new" concepts ANALES DE MEDICINA INTERNA
Artículo1999 Correlation between gender and spontaneous C-cell tumors in the thyroid gland of the Wistar rat CELL AND TISSUE RESEARCH
Artículo1999 Desmoplasmatic small round cell tumor Oncología
Letter1998 Paragangliomas: Presentation of one case and review of the diagnostic process and treatment [1] Neoplasia (Spanish Edition)
Artículo1998 Primary non Hodgkin ovarian lymphoma associated with dermatomyositis and autoimmune anemia by cold antibodies Neoplasia (Spanish Edition)
Artículo1997 Prospective study with dacarbacin plus alpha interferon 2b as first line therapy in metastatic melanoma Neoplasia (Spanish Edition)
Artículo1997 Tolerance and efficacy study on alpha 2b interferon plus vinblastine in metastatic renal cell carcinoma Neoplasia (Spanish Edition)

Proyectos de Investigación

Fecha de inicio Fecha de fin Rol Denominación Agencia financiadora
01/01/2014 31/12/2016 Investigador/a Marcadores de cáncer stem cells en carcinoma microcítico de pulmón: valoración pronóstica y uso como dianas específicas para el desarrollo de terapias avanzadas mediante nanotransportadores dirigidos (PI-0051-2013) Consejería de Salud y Bienestar Social (Fundación Progreso y Salud) (Autonómico)
13/01/2009 13/01/2012 Investigador/a Estudio del Papel Regulador de los Péptidos Orexigénicos y Anorexigénicos Producidos por las Células C a Nivel del Tiroides sobre la Síntesis de Hormonas Tiroideas (P08-CVI-03598) Junta de Andalucía - Consejería de Innovación, Ciencia y Empresas (Autonómico)
El investigador no tiene ningún resultado de investigación asociado